EarliVice President, Therapeutics
May 2025Redwood City, California, United States
David Rosen ♦ 17+ year pre-clinical pharmacology director in Immunology and Oncology biologics drug development ♦ Adept with various modalities including: Engineered cytokines, chimeric receptors, Genotoxins, Multispecific Antibodies (Fc, KiH, VHH, and Tumor-Immune bispecific engagers), ADCs, Immune Checkpoint antagonists, Innate immune agonists, Immune Costimulation agonists, Kinase inhibitors ♦ Led programs/teams throughout development from idea conception to clinical trials ♦ Planned, authored 12+ patents, 23+ manuscripts, IND-preclinical pharmacology summaries / reports ♦ Worked in both startup and big pharma environments, including new lab design / setup ♦ Prepared and ran SAB meetings, recruited external scientific/clinical consultants ♦ Supported academic and corporate collaborations and successful in- and out-licensing BD deals ♦ Managed internal experiments and CROs for in vitro characterization / validation, in vivo mouse efficacy studies, NHP PK/PD/Biomarker studies, and NHP GLP Tox studies ♦ Scientific lead for biased IL-2 (Ph1) and biased IL-12 (IND in preparation) I/O programs ♦ Scientific lead for VHH checkpoint antagonist and bispecific NK engager projects from immunization, se
David Rosen ♦ 17+ year pre-clinical pharmacology director in Immunology and Oncology biologics drug development ♦ Adept with various modalities including: Engineered cytokines, chimeric receptors, Genotoxins, Multispecific Antibodies (Fc, KiH, VHH, and Tumor-Immune bispecific engagers), ADCs, Immune Checkpoint antagonists, Innate immune agonists, Immune Costimulation agonists, Kinase inhibitors ♦ Led programs/teams throughout development from idea conception to clinical trials ♦ Planned, authored 12+ patents, 23+ manuscripts, IND-preclinical pharmacology summaries / reports ♦ Worked in both startup and big pharma environments, including new lab design / setup ♦ Prepared and ran SAB meetings, recruited external scientific/clinical consultants ♦ Supported academic and corporate collaborations and successful in- and out-licensing BD deals ♦ Managed internal experiments and CROs for in vitro characterization / validation, in vivo mouse efficacy studies, NHP PK/PD/Biomarker studies, and NHP GLP Tox studies ♦ Scientific lead for biased IL-2 (Ph1) and biased IL-12 (IND in preparation) I/O programs ♦ Scientific lead for VHH checkpoint antagonist and bispecific NK engager projects from immunization, se
Career
Self EmployedIndependent Consultant
Sep 2024
SynthekineSenior Director, Research
Sep 2022 — Sep 2024Menlo Park, California, United States
Ascendis PharmaSenior Director, Adaptive Immunology (ImmunoOncology)
Jan 2022 — Aug 2022Redwood City, California, United States
Ascendis PharmaDirector, Adaptive Immunology
Nov 2018 — Jan 2022Palo Alto, California, United States
University of California, San FranciscoGraduate Student Researcher
Jan 2002 — Jan 2007